Skip to main content
OpenTrials
Completed

NCT Number: NCT02058992

Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty

The purpose of this study is to investigate the safety and efficacy of ramelteon (Rozerem) when used in the routine clinical setting in patients with sleep-onset difficulty associated with insomnia.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This is a drug use surveillance planned to examine the safety and efficacy of ramelteon tablets when used in the routine clinical setting in patients with sleep-onset difficulty associated with insomnia (planned sample size, 3000)

The usual adult dosage is 8 mg of ramelteon administered orally once daily at bedtime.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sleep-onset difficulty associated with insomnia

Exclusion criteria

  • Patients with previous history of hypersensitivity to an ingredient of Rozerem Tablets
  • Patients with severe liver dysfunction
  • Patients taking fluvoxamine maleate

Treatment and study plan

Ramelteon

Drug

Ramelteon 8 mg tablets

Other names: Rozerem

Primary outcomes

  1. Number of Participants Reporting One or More Adverse Drug Reactions

    Time frame: Baseline up to 6 weeks

    Adverse drug reactions are defined as adverse events (AE) which are in the investigator's opinion of causal relationship to the study treatment. AE are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug.

  2. Number of Participants Reporting One or More Serious Adverse Drug Reactions

    Time frame: Baseline up to 6 weeks

    Serious adverse drug reactions are defined as serious adverse events (SAE) which are in the investigator's opinion of causal relationship to the study treatment. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Secondary outcomes

  1. Sleep Status: Sleep Onset Latency

    Time frame: Baseline and Week 4

    Sleep status was determined by measuring the sleep onset latency, defined as the length of time taken from lying down for the night until sleep onset.

  2. Sleep Status: Total Sleep Time

    Time frame: Baseline and Week 4

    Sleep status was determined by measuring the total sleep time, defined as the amount of actual sleep time during a sleep episode.

  3. Sleep Status: Number of Awakenings

    Time frame: Baseline and Week 4

    Sleep status of participants was assessed and summarized by calculating the number of times participants had awaken from the time of start of the investigation.

  4. Percentage of Participants Who Responded With Improvement on the Patient Global Impression (PGI) Scale at Week 4

    Time frame: Week 4

    PGI is a participant rated instrument to measure participant's change in overall status on a 7-point scale. 7 items on scale include sleep onset, sleep time, sleep quality, morning awakening, morning tiredness, daytime somnolence, and daytime physical condition/function. Participants provide their response on a PGI questionnaire. The results of survey using the PGI questionnaire was scored, summarized and assessed. Total score range from 1 (very much improved) to 7 (very much worse). Percentage of participants with improvement rated as "much better" or "a little better" were reported for sleep onset,time, quality; morning awakening, tiredness and daytime sleepiness, physical condition.

Sponsors and collaborators

Lead sponsor

Takeda

Industry

Registry information

Official study title

Rozerem Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty

Important dates

Study start
2010
Primary completion
2013
Study completion
2013
First posted
Feb 11, 2014
Registry last updated
Jul 14, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.